Treatment options for patients with brain metastases from EGFR / ALK -driven lung cancer

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text

Medicine, Oncology, Pharmacology +13

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

Benjamin Solomon, Tony Mok, Dong‐Wan Kim et al. · New England Journal of Medicine · 2014 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +12

A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain

Roy A. Patchell, Phillip A. Tibbs, John W. Walsh et al. · New England Journal of Medicine · 1990 · 3.2K citations · Full text

Medicine, Oncology, Surgery +17

Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial

Eric L. Chang, Jeffrey S. Wefel, Kenneth R. Hess et al. · The Lancet Oncology · 2009 · 2.5K citations

Medicine, Neurosurgery, Oncology +13